Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Anti-Cancer Drugs|May 1, 1996
Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administrationH D Bear, A W McFadden, P J Kostuchenko, et al.
Annals of Surgery|June 1, 1996
Long-term results of breast conservation therapy for breast cancerP T Neff, H D Bear, C V Pierce, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2000
Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservationD W Arthur, R K Schmidt-Ullrich, R B Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04N Wolmark, H Rockette, E Mamounas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Effect of preoperative chemotherapy on the outcome of women with operable breast cancerB Fisher, J Bryant, N Wolmark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2007
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006M Kaufmann, G von Minckwitz, H D Bear, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2023
Effect of preoperative chemotherapy on the outcome of women with operable breast cancerB Fisher, J Bryant, N Wolmark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2025
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-BS Loibl, M Martin, H Bonnefoi, et al.
Pageof 6